U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...
This past weekend, Lilly Pulitzer, the originator of American Resort Wear, made a momentous return to the runway, a first for ...
In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...
Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...
Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a two-year ...
But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...
The drugmaker Ely Lilly (NYSE: LLY) has had a very successful run over the long run. Shares currently trade around $818 and ...
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...
Now, we already know that Johnny Depp and Vanessa Paradis‘ daughter Lily-Rose Depp is her supermodel mom’s lookalike, but now ...